ABL Bio Future Growth
Future criteria checks 0/6
ABL Bio's revenue is forecast to decline at 2.5% per annum while its annual earnings are expected to grow at 16.7% per year. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be -58.5% in 3 years.
Key information
16.7%
Earnings growth rate
16.1%
EPS growth rate
| Biotechs earnings growth | 50.4% |
| Revenue growth rate | -2.5% |
| Future return on equity | -58.5% |
| Analyst coverage | Low |
| Last updated | 04 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Is ABL Bio (KOSDAQ:298380) Using Too Much Debt?
May 29
Is ABL Bio (KOSDAQ:298380) Weighed On By Its Debt Load?
Feb 26We Think ABL Bio (KOSDAQ:298380) Can Afford To Drive Business Growth
Mar 31Should ABL Bio (KOSDAQ:298380) Be Disappointed With Their 33% Profit?
Jan 20
Companies Like ABL Bio (KOSDAQ:298380) Are In A Position To Invest In Growth
Dec 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 33,000 | N/A | N/A | -32,600 | 1 |
| 12/31/2025 | 28,000 | -29,000 | -97,000 | -97,000 | 1 |
| 12/31/2024 | 35,000 | -22,000 | -89,000 | -89,000 | 1 |
| 3/31/2024 | 33,103 | -38,952 | -67,776 | -60,555 | N/A |
| 12/31/2023 | 65,547 | -2,647 | -34,206 | -28,362 | N/A |
| 9/30/2023 | 67,446 | -7,951 | 1,252 | 4,155 | N/A |
| 6/30/2023 | 97,254 | 23,608 | 5,534 | 8,498 | N/A |
| 3/31/2023 | 104,803 | 36,101 | 9,863 | 12,230 | N/A |
| 12/31/2022 | 67,301 | 3,209 | 69,746 | 72,132 | N/A |
| 9/30/2022 | 57,994 | 4,352 | 43,645 | 44,605 | N/A |
| 12/31/2021 | 5,332 | -43,558 | -41,871 | -40,605 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A298380 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: A298380 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: A298380 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: A298380's revenue is expected to decline over the next 3 years (-2.5% per year).
High Growth Revenue: A298380's revenue is forecast to decline over the next 3 years (-2.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A298380 is forecast to be unprofitable in 3 years.